PipelineReview.com - All Products

Show Cart

All Products

Results 101 - 120 of 194

May 2016 Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Apr 2016 Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Mar 2016 Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins

Feb 2016 Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

Feb 2016 Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines

Feb 2016 Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

Feb 2016 RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

Jan 2016 Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

Nov 2015 Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis

Sep 2015 Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines

Sep 2015 Competitor Analysis: Interleukin-4/-13 (IL-4/-13) Inhibitors or Receptor Antagonists

Sep 2015 Competitor Analysis: Sphingosine-1-Phosphate (S1P) Receptor Modulators

Sep 2015 Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists

Aug 2015 Competitor Analysis: Interleukin-17/Receptor (IL-17/R) Antagonists

Jul 2015 Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

Mar 2015 2014 Sales of Recombinant Therapeutic Antibodies & Proteins

Mar 2015 Engineered TCR and CAR Immunotherapeutics 2015

(Discount: 20.00%)

Feb 2015 Competitor Analysis: Specific and Bispecific Her3 Antibodies

Shopping cart

Cart empty

Latest report

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Shopping cart

Cart empty

Latest report

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

La Merie Biologics

FREE Weekly News Bulletin

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing